Your browser is no longer supported. Please, upgrade your browser.
Chemomab Therapeutics Ltd.
Index- P/E- EPS (ttm)-100.13 Insider Own0.40% Shs Outstand0.12M Perf Week-13.19%
Market Cap454.58M Forward P/E- EPS next Y-9.92 Insider Trans0.00% Shs Float0.05M Perf Month-29.06%
Income-11.60M PEG- EPS next Q- Inst Own0.70% Short Float24.27% Perf Quarter-1.12%
Sales- P/S- EPS this Y60.30% Inst Trans-23.28% Short Ratio0.05 Perf Half Y84.24%
Book/sh30.86 P/B1.12 EPS next Y- ROA-118.90% Target Price- Perf Year147.77%
Cash/sh0.41 P/C84.18 EPS next 5Y- ROE-162.10% 52W Range12.00 - 168.80 Perf YTD24.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.57% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low187.42% ATR10.72
Employees3 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)45.89 Volatility29.44% 25.90%
OptionableNo Debt/Eq0.00 EPS Q/Q61.70% Profit Margin- Rel Volume7.00 Prev Close27.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume258.29K Price34.49
Recom3.00 SMA20-1.49% SMA50-34.62% SMA20014.06% Volume1,629,994 Change26.52%
Mar-29-21 09:00AM  
Mar-22-21 07:00AM  
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.